Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better-Reference-Cited by-同舟云学术

Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better

Published:2008-03-01 Issue:3 Volume:13 Page:277-283
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Fojo Tito¹

Affiliation:

1. Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Abstract

Abstract In the era of targeted therapy, many have argued that targeted therapies would not only be more effective but also less toxic. However, the early evidence suggests that the assumption that greater specificity would result in greater efficacy may have been premature. In fact, it can be argued that dirty may be better than clean.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2007-0090

Reference60 articles.

1. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference summary statement;Come;Clin Cancer Res,2005

2. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer;Jordan;Steroids,2007

3. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer;Coombes;Lancet,1984

4. Tipifarnib: Farnesyl transferase inhibition at a crossroads;Mesa;Expert Rev Anticancer Ther,2006

5. Anti-cancer therapy: Targeting the mevalonate pathway;Swanson;Curr Cancer Drug Targets,2006

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signal Transduction Inhibitors;Therapeutic Strategies in Veterinary Oncology;2023-08-23

2. Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse;Scientific Reports;2022-03-31

3. Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model;Scientific Reports;2022-03-25

4. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action;JAMA Network Open;2021-12-14

5. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?;Journal of Clinical Oncology;2021-11-01